Literature DB >> 1941609

Binding of [3H]AF-DX 384 to cloned and native muscarinic receptors.

J H Miller1, V A Gibson, M McKinney.   

Abstract

The binding selectivity of [3H]AF-DX 384 [(+-)-5,11-dihydro-11- ([(2-(2-[(dipropylamino)methyl]-1- piperidinyl)ethyl)amino]carbonyl)-H-pyrido(2,3-b)(1,4)benzodiazepine-6-o ne] was evaluated with cloned human muscarinic receptors (M1-M4) in Chinese hamster ovary (CHO-K1) cell lines as well as in rat heart and brain. There were uniform classes of sites for the radioligand in the M2-rich tissues, heart (Kd = 2.3 nM) and brainstem (Kd = 2.4 nM). However, [3H]AF-DX 384 bound to all four cloned receptor subtypes. Using kinetic methods, the calculated Kd values were M2 (1 nm) greater than M4 (2.2 nM) greater than M3 (15 nM) greater than M1 (55 nM). Scatchard analysis with the CHO cells confirmed the high affinity of this radioligand for the M2 (1.8 nM) and M4 (2.5 nM) receptors. To evaluate the potential for selectively binding to M2 and M4 receptors in cortex and striatum, low concentrations (0.5-0.8 nM) of the radioligand were used and a two-site competition model was used to derive the binding constants for pirenzepine and AF-DX 116 [(+-)-11-2((-((diethylamino) methyl)-1-piperidinyl)acetyl)-5,11-dihydro-6H- pyrido(2,3-b)(1,4)-benzodiazepine-6-one] and to compare them with values obtained with cloned M2 and M4 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1941609

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Bidirectional modulation of visual plasticity by cholinergic receptor subtypes in the frog optic tectum.

Authors:  Chuan-Jiang Yu; Christopher M Butt; Elizabeth A Debski
Journal:  Eur J Neurosci       Date:  2003-03       Impact factor: 3.386

2.  Acetylcholine-dependent upregulation of TASK-1 channels in thalamic interneurons by a smooth muscle-like signalling pathway.

Authors:  Michael Leist; Susanne Rinné; Maia Datunashvili; Ania Aissaoui; Hans-Christian Pape; Niels Decher; Sven G Meuth; Thomas Budde
Journal:  J Physiol       Date:  2017-08-03       Impact factor: 5.182

3.  Pharmacology, distribution and development of muscarinic acetylcholine receptor subtypes in the optic tectum of Rana pipiens.

Authors:  C M Butt; J R Pauly; L H Wilkins; L P Dwoskin; E A Debski
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

4.  Muscarinic receptor/G-protein coupling is reduced in the dorsomedial striatum of cognitively impaired aged rats.

Authors:  Erasmo Nieves-Martinez; Kathryn Haynes; Steven R Childers; William E Sonntag; Michelle M Nicolle
Journal:  Behav Brain Res       Date:  2011-11-07       Impact factor: 3.332

5.  Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects.

Authors:  A S Gibbons; E Scarr; C McLean; S Sundram; B Dean
Journal:  J Affect Disord       Date:  2008-12-21       Impact factor: 4.839

6.  Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.

Authors:  Elizabeth Scarr; Catriona McLean; Brian Dean
Journal:  J Neural Transm (Vienna)       Date:  2016-09-29       Impact factor: 3.575

7.  Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants.

Authors:  Andrew Stuart Gibbons; Won Je Jeon; Elizabeth Scarr; Brian Dean
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-20       Impact factor: 5.176

8.  Structural insights into the subtype-selective antagonist binding to the M2 muscarinic receptor.

Authors:  Ryoji Suno; Sangbae Lee; Shoji Maeda; Satoshi Yasuda; Keitaro Yamashita; Kunio Hirata; Shoichiro Horita; Maki S Tawaramoto; Hirokazu Tsujimoto; Takeshi Murata; Masahiro Kinoshita; Masaki Yamamoto; Brian K Kobilka; Nagarajan Vaidehi; So Iwata; Takuya Kobayashi
Journal:  Nat Chem Biol       Date:  2018-11-12       Impact factor: 15.040

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.